Unknown PHASE1 INTERVENTIONAL 4-arm NCT01218880

Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer

Phase I Study of M2ES Combined Gemcitabine in Patients With Advanced Pancreatic Cancer

Sponsor: Protgen Ltd

Interventions M2ES 15mg M2ES 30mg M2ES 45mg M2ES 7.5mg

Updated 5 times since 2017 Last updated: Oct 18, 2010 Started: Jun 30, 2010 Primary completion: Jul 31, 2011 Completion: Dec 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Pancreatic Cancer, this trial is ongoing. The trial is conducted by Protgen Ltd and has accumulated 5 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE1

First recorded

Jun 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Protgen Ltd

Data source: Protgen Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China